SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: BioMarin headquarters in California/iSto
Layoffs
BioMarin to Lay Off 225 Employees Globally
Last week, BioMarin revealed changes to its C-suite; now, the company has announced its second round of layoffs this year, following the termination of 170 employees in May.
August 29, 2024
 · 
1 min read
 · 
Angela Gabriel
Drug Development
Future-Proofing: Inclusive and Protective Patient Strategies
In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori and guests discuss framing strategies designed to protect DEI initiatives from legal challenges.
August 29, 2024
 · 
1 min read
 · 
Lori Ellis
Merck Research Laboratories in South San Francisco, California
Cancer
Merck Axes Two Keytruda Phase III Cancer Trials Due to Disappointing Data
The pharma continued its clinical losing streak on Thursday with the announcement that it is discontinuing late-stage studies of the anti-PD-1 therapy in non-small cell lung cancer and cutaneous squamous cell carcinoma.
August 29, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of the U.S. Capitol building
Pharmacy benefit managers
House Oversight Chair Calls on PBM Execs to Correct Testimonies
The chair of the House Committee on Oversight and Accountability wants the CEOs of CVS Caremark, Express Scripts and Optum Rx to fix statements they made in a hearing last month that contradicted the committee’s and Federal Trade Commission’s findings.
August 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Photo of a judge's gavel, a balance and a stack of papers
Legal
Regeneron Sues Sandoz in Federal Court to Block Eylea Biosimilar
In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.
August 29, 2024
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Cardiovascular disease
Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study
Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease.
August 29, 2024
 · 
2 min read
 · 
Tristan Manalac
broken human head conceptual digital illustration
Drug Development
Neurocrine Shares Drop 20% Despite Meeting Primary Endpoint in Mid-Stage Schizophrenia Trial
Neurocrine Biosciences’ potential competitor to Bristol Myers Squibb’s KarXT improved symptoms of schizophrenia in a Phase II trial, but only at the low dose tested.
August 28, 2024
 · 
2 min read
 · 
Annalee Armstrong
Stack of documents. Pile of waste documents earmarked for Recycling.
Patents
Patent Thickets in Federal Government’s Crosshairs as Election 2024 Looms
Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition.
August 28, 2024
 · 
7 min read
 · 
Greg Slabodkin
Feb 2, 2020 South San Francisco / CA / USA - Genentech headquarters in Silicon Valley; Genentech, Inc., is an American biotechnology corporation which became a subsidiary of Roche in 2009
Layoffs
Genentech to Lay Off 93 in San Francisco
Genentech’s latest layoffs are the second round of workforce reductions this year, following the company’s announcement in April that it was letting go around 3% of employees.
August 28, 2024
 · 
1 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS